Could a simple shot replace IV drips for nausea?
NCT ID NCT02466984
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether metoclopramide, a common anti-nausea drug, works as well when injected under the skin (subcutaneous) as when given through a vein (IV). Five patients in a palliative care unit received the drug both ways to compare absorption. The goal is to offer a more comfortable and convenient option for managing nausea and vomiting.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- metoclopramide (Primperan)
- What this could lead to
- If it works, this could provide a simpler, less invasive way to give metoclopramide for nausea and vomiting in patients who cannot take oral medication.
- What could go wrong
- This is a very small study (5 participants) in a specific palliative care setting, so results may not apply broadly. The drug's effectiveness via subcutaneous route is still unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
5 people
The number who actually took part.
- Started
-
Jul 2016
- Finished
-
Feb 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Man or woman \> 18 years * Patients hospitalized at the palliative medical care unit of University Hospital Bordeaux * Patient whose life expectancy is greater to 4 weeks * Patients suffering from nausea the day of inclusion with a greater than or equal score to 3/10 on a numerical scale (FR) from 0 to 10 and / or have had at least one vomiting within three days prior to inclusion * Patients may be infused through an IV and subcutaneous (SC) * Patient can communicate verbally or in writing * Patients affiliates or beneficiaries of a social security fund * Patient has given his written consent Exclusion criteria * Pregnant or breastfeeding women * Current Treatment for severe and progressive threatening disease * Treatment with oral or injectable metoclopramide within 3 days prior to inclusion * Treatment with levodopa or dopamine agonists in progress * Neuroleptic Processing * Patient with lesion occlusive syndrome * Patients at risk of gastrointestinal perforation * Patient with clinical signs of gastrointestinal bleeding * Parkinson's disease * Patients with epilepsy not controlled by anti-seizure treatment * Patients suffering from liver failure * Patients with a heart rate less than 60 beats / min at baseline * Patients with systolic blood pressure less than or equal to 90 mmHg at baseline * History of allergy to metoclopramide * History of allergy to ondansetron * Previous history of tardive dyskinesia to neuroleptics or metoclopramide * Previous history of pheochromocytoma * Previous history of methemoglobinemia with metoclopramide * History of deficit NADH-cytochrome b5 reductase * Patient deprived of liberty by judicial or administrative decision * Major protected by law * Exclusion period Patient relative over another protocol. Exclusion criteria * Pregnant woman (blood β-HCG dosage ≥ 5 IU / L) * Patients with a creatinine clearance less than or equal to 60 mL / min at baseline * Patient with cardiac conduction disorders on ECG * Patients with electrolyte imbalance in electrolytes
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nausea are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier Universitaire de Bordeaux - St André
Bordeaux, Aquitaine, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a foot massage ease Post-Surgery pain and anxiety?
- Could a botox shot in the gut ease Kids' chronic vomiting?
- Can a daily capsule ease bloating and boost energy?
- Simple breathing exercises after gallbladder surgery may cut pain and nausea
- Could a Steroid-Sparing cocktail tame chemo nausea?
- Plasma power: new endoscopic treatment could heal Post-Bypass ulcers faster